Advisors Preferred’s Vertex Pharmaceuticals VRTX Stock Holding History

Advisors Preferred’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,200	Closed	-$995K	–	302
2025 Q2	$995K	Hold	2,200	–	–	0.16%	100
2025 Q1	$1.07M	Buy	+2,200	New	+$1.03M	0.14%	108
2023 Q4	–	Sell	-9,633	Closed	-$3.35M	–	299
2023 Q3	$3.35M	Sell	9,633 -7,353	-43%	-$2.57M	1.09%	24
2023 Q2	$5.9M	Buy	+16,986	New	+$5.72M	1.46%	14
2022 Q2	–	Sell	-2,921	Closed	-$777K	–	199
2022 Q1	$777K	Buy	+2,921	New	+$693K	0.06%	63
2021 Q2	–	Sell	-913	Closed	-$195K	–	229
2021 Q1	$195K	Buy	+913	New	+$201K	0.03%	125
2020 Q1	–	Sell	-205	Closed	-$45K	–	271
2019 Q4	$45K	Buy	+205	New	+$41.5K	0.01%	192
2018 Q4	–	Sell	-392	Closed	-$76K	–	222
2018 Q3	$76K	Buy	+392	New	+$69.8K	0.03%	105

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Advisors Preferred's VRTX Position: Q3 2025 in Review

Advisors Preferred sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 2,200 shares — an estimated $995K sold.

Advisors Preferred first reported a position in VRTX in Q3 2018 and held it in 8 quarters. The position peaked at $5.9M in Q2 2023. 1,520 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

Advisors Preferred reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Advisors Preferred sold 2,200 Vertex Pharmaceuticals shares in Q3 2025, an estimated $995K.
Advisors Preferred first reported a position in Vertex Pharmaceuticals in Q3 2018 and held it in 8 quarters.
Advisors Preferred's Vertex Pharmaceuticals position peaked at $5.9M in Q2 2023.
1,520 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Advisors Preferred's 13F filing for Q3 2025, filed 10 Nov 2025.